Related Experiment Video

Updated: Jan 17, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K

The Roles, Mechanisms, and Clinical Significance of Long Non-coding RNA MSC-AS1 in Cancer

Jingjie Yang1,2, Fan Peng1,2, Kexing Liu1,2

  • 1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.

Mini Reviews in Medicinal Chemistry
|September 18, 2025
PubMed

Insights

Musculin antisense RNA 1 (MSC-AS1), a long non-coding RNA, is dysregulated in numerous cancers. Its aberrant expression impacts tumor progression and patient outcomes, highlighting its potential as a cancer biomarker and therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Musculin antisense RNA 1 (MSC-AS1) is a long non-coding RNA (lncRNA) implicated in various human cancers.
  • Its expression is altered in 16 cancer types, correlating with clinical features and prognosis in 12.

Purpose of the Study:

  • To review the role of MSC-AS1 in cancer, including its expression patterns, functional roles, and molecular mechanisms.
  • To evaluate MSC-AS1 as a potential cancer biomarker and therapeutic target.

Main Methods:

  • Literature review of studies investigating MSC-AS1 in human cancers.
  • Analysis of MSC-AS1 expression, functional impacts, and mechanistic pathways.

Main Results:

  • MSC-AS1 dysregulation is linked to tumor growth, metastasis, epithelial-mesenchymal transition (EMT), metabolic reprogramming, and drug resistance.
  • MSC-AS1 functions as a competing endogenous RNA (ceRNA) sponging miRNAs and directly interacts with proteins, activating PI3K/AKT and Wnt/β-catenin pathways.

Conclusions:

  • MSC-AS1 plays a significant role in the development and progression of various cancers.
  • MSC-AS1 holds promise as a diagnostic biomarker and a therapeutic target for cancer treatment.
Keywords:
CancerLncRNAMSC-AS1biomarkeroligonucleotides.therapeutic target

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.8K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K